Jan 11, 2023 / 05:45PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the conference today with Ionis. A little different format this year than in years past. So no switching rooms for Q&A. We're going to stay right in here.
If you have a question, you can raise your hand, somebody will run over to you with a microphone. Or alternatively, you can submit questions electronically and I'll read them off the iPad up here. So with that out of the way, let me turn it over to Ionis CEO, Brett Monia.
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Thank you very much, Jess. Good morning, everybody. I'm really pleased to provide you with an update on the great progress we're making at Ionis. So these are my forward-looking statements that I recommend for you to review at your convenience. 3 years ago, when I became the CEO of Ionis, I laid out 4 strategic priorities for Ionis to bring Ionis to even greater success, to
Ionis Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers